Earnings Call Summary | Addex Therapeutics(ADXN.US) Q1 2024 Earnings Conference
Earnings Call Summary | Addex Therapeutics(ADXN.US) Q1 2024 Earnings Conference
The following is a summary of the Addex Therapeutics Ltd (ADXN) Q1 2024 Earnings Call Transcript:
以下是Addex Therapeutics Ltd（ADXN）2024年第一季度業績會議交流的摘要:
Financial Performance:
金融業績：
Addex Therapeutics reported a revenue of CHF0.2 million in Q1 2024, primarily from research funding.
R&D expenses for the GABAB PAM program were stable at CHF0.3 million.
General and Administrative expenses increased due to legal fees related to the Neurosterix transaction.
After the Neurosterix transaction, they recognized CHF5 million, enhancing their balance sheet with total assets primarily held in cash.
Addex Therapeutics報告2024年第一季度營業收入爲20萬瑞士法郎，主要來自研究資金。
GABAB PAM項目的研發費用保持穩定，爲30萬瑞士法郎。
由於與Neurosterix交易有關的法律費用增加，一般和行政費用增加。
Neurosterix交易後，他們認可了500萬瑞士法郎，增強了他們的資產負債表，主要以現金爲主。
Business Progress:
業務進展：
Launched Neurosterix with a Series A funding of $63 million.
Partnership with Indivior advancing with a funded GABAB modulator program for substance use disorders.
Development of dipraglurant for post-stroke recovery advanced.
Preparing to start IND enabling studies for their independent GABAB cough program.
以6300萬美元的A輪資金推出Neurosterix。
與Indivior的合作推進，資助GABAB調製劑計劃用於物質使用障礙。
推進dipraglurant用於發帖後恢復的開發。
準備開始獨立的GABAB咳嗽項目的IND實現研究。
Opportunities:
機會：
The differentiation of dipraglurant for post-stroke recovery catering to a large unmet medical need in rehabilitation therapies.
Potential expansions in partnering for dipraglurant in various unmet medical areas.
Advancing M4 PAM, mGlu7NAM, and mGlu2NAM programs with secured financing in the specialized entity, Neurosterix.
dipraglurant用於發帖後康復的差異性應對龐大的康復治療領域中尚未得到滿足的醫療需求。
在各種未滿足的醫學領域中擴大合作伙伴關係以擴大dipraglurant的潛力。
在專門的實體Neurosterix中通過獲得融資推進M4 PAM，mGlu7NAM和mGlu2NAM計劃。
Risks:
風險：
The epilepsy program with Janssen did not meet its primary endpoint, raising uncertainties about the future of this collaboration.
與Janssen的癲癇項目未達到主要終點，增加了該合作關係未來的不確定性。
More details: Addex Therapeutics IR
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：如需更全面的詳情，請參閱投資人關係網站。本文僅供投資者參考，不作任何指引或建議。
譯文內容由第三人軟體翻譯。